Ipsen shares drop after FDA approval of U.S. generic rival
Ipsen shares fell 6.6% to a seven-month low of 145.60 euros in morning European trade after the FDA approved a U.S. generic competitor to Ipsen’s flagship hormone drug earlier than expected.
Ipsen shares fell sharply after the U.S. Food and Drug Administration approved a generic competitor to its flagship hormone drug sooner than expected. Shares were down 6.6% to a seven-month low of 145.60 euros in morning European trade, making Ipsen the worst performer in the Europe-wide St…